Barely Significant
← all excerpts

The Evolution of Targeted Therapies in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer.

Cancers (Basel) · 2026 · PMC13072393 · PMID 41976354

Europe PMCDOI
1
hedged sentence
0.0480
closest p · 1.0× alpha
0.0480
boldest claim

The sentences

showed a trendp = 0.048actually significant
The NSABP B-42 trial, which randomized patients after five years of tamoxifen or AI to another five years of letrozole or placebo, showed a trend toward improved DFS at seven years (84.7% vs. 81.3%, HR 0.85, p = 0.048).

also in 33,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.